Even when feasible and forthcoming, randomized clinical trials cannot be conducted quickly enough to answer urgent questions about the safety and efficacy of treatments in the context of evolving variants of COVID-19. This limitation is particularly important for patient subgroups who are not well represented or for whom treatment effects cannot be precisely estimated in clinical trials. Rigorous observational treatment comparisons can fill this gap and supplement what we learn from clinical trials.
